What is the appropriate evaluation and management for a patient with fasting-related morning abdominal pain suggestive of peptic ulcer?

Fasting-Related Morning Abdominal Pain: Evaluation and Management

For a patient with morning abdominal pain occurring during fasting, you should pursue a test-and-treat strategy for H. pylori in patients under 55 years without alarm symptoms, or proceed directly to endoscopy in those ≥55 years or with alarm features, followed by PPI therapy as first-line treatment for confirmed peptic ulcer disease. 1

Initial Risk Stratification and Diagnostic Approach

The evaluation pathway depends critically on age and presence of alarm features:

Patients Requiring Urgent/Non-Urgent Endoscopy:

• ≥55 years with weight loss → urgent endoscopy 1
• >40 years from high gastric cancer risk areas or with family history of gastro-oesophageal cancer → urgent endoscopy 1
• ≥55 years with treatment-resistant dyspepsia, raised platelet count, nausea, or vomiting → non-urgent endoscopy 1
• ≥60 years with abdominal pain AND weight loss → urgent abdominal CT to exclude pancreatic cancer 1

Patients Suitable for Test-and-Treat Strategy:

• All other patients without alarm features should receive non-invasive H. pylori testing (stool antigen or urea breath test—NOT serology) 1
• This approach is cost-effective and ranks first among management strategies for reducing symptoms at 12 months 1

Treatment Algorithm

If H. pylori Positive:

Eradication therapy is the priority, as H. pylori accounts for approximately 42% of peptic ulcer disease cases 2. The treatment hierarchy is:

1. First-line: Vonoprazan-based triple therapy (vonoprazan + 2 antibiotics) is superior to conventional PPI-based regimens, with eradication rates of 92% vs 80% 3, 4

2. Second-line: PPI-based therapy if vonoprazan unavailable, using bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days 5

3. Confirm eradication at least 4 weeks post-treatment in patients at increased gastric cancer risk 1, 4

If H. pylori Negative:

Empirical acid suppression with PPIs is first-line therapy 1:

• PPIs heal 80-100% of peptic ulcers within 4 weeks (gastric ulcers >2 cm may require 8 weeks) 2
• Use the lowest effective dose to control symptoms 1
• Standard PPIs (omeprazole, lansoprazole) are appropriate first-line agents 3
• P-CABs (vonoprazan) should NOT be used as first-line therapy for peptic ulcer treatment given higher costs and limited availability, though they are noninferior to PPIs 3

NSAID-Related Considerations

If the patient uses NSAIDs or aspirin (accounting for 36% of peptic ulcer disease) 2:

• Discontinue NSAIDs if possible → heals 95% of ulcers and reduces recurrence from 40% to 9% 2
• If NSAIDs cannot be stopped: Add PPI therapy, which is recommended for ulcer prevention in patients with ulcer history 6
• For low-dose aspirin users with ulcer history: PPIs or vonoprazan are recommended for prevention 6

Critical Pitfalls to Avoid

1. Do NOT use H. pylori serology for diagnosis—specificity is too low; use stool antigen or breath testing 1

2. Do NOT routinely confirm H. pylori eradication in all patients—only in those at increased gastric cancer risk 1

3. Do NOT perform gastric emptying testing or 24-hour pH monitoring routinely in typical dyspepsia 1

4. Fasting itself does not increase peptic ulcer incidence in uncomplicated cases, though patients with active chronic ulcers may be at higher risk during prolonged fasting 7. Patients can fast if taking medications appropriately 8

When Symptoms Persist

For treatment-resistant cases after first-line therapy:

• Tricyclic antidepressants (amitriptyline 10 mg, titrated to 30-50 mg daily) are efficacious second-line treatment for functional dyspepsia 1
• Consider referral to gastroenterology for severe or refractory symptoms, diagnostic uncertainty, or patient request 1
• Re-evaluate for complications: bleeding (73% of complications), perforation (9%), or pyloric obstruction (3%) 2